Japan Patent For Cyclosporin Brain-Protection Granted To Maas BiolAB
10/19/2005 5:09:57 PM
ALBUQUERQUE, N.M.--(BUSINESS WIRE)--May 19, 2005--Maas BiolAB, LLC announced that the Japan Patent Office has granted patent number 3643380. The Maas Japan patent is for Cyclosporin Neuroprotection treating the gamut of neurological diseases. Cyclosporin has been shown to be a powerful and effective neuroprotectant in preclinical models of neurological diseases from traumatic brain injury to amyotrophic lateral sclerosis (ALS). Japan, with a population of 127 million people, is the second largest pharmaceutical market in the world.
Maas BiolAB has been granted patents in 36 countries including North America (USA, Canada, Mexico), Europe (Austria, Belgium, Czech Republic, Denmark, France, Germany, Greece, Ireland, Italy, Latvia, Lithuania, Luxembourg, Monaco, Netherlands, Portugal, Slovenia, Spain, Sweden, Switzerland, United Kingdom), Africa (Ghana, Kenya, Lesotho, Malawi, Sudan, Swaziland, Uganda, Zimbabwe), Antipodes (Australia, New Zealand), Russia, China, and now Japan.